445 related articles for article (PubMed ID: 32107536)
1. Pharmacoepidemiology of Ceftazidime-Avibactam Use: A Retrospective Cohort Analysis of 210 US Hospitals.
Strich JR; Ricotta E; Warner S; Lai YL; Demirkale CY; Hohmann SF; Rhee C; Klompas M; Palmore T; Powers JH; Dekker JP; Adjemian J; Matsouaka R; Woods CW; Danner RL; Kadri SS
Clin Infect Dis; 2021 Feb; 72(4):611-621. PubMed ID: 32107536
[TBL] [Abstract][Full Text] [Related]
2. Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance.
Shields RK; Nguyen MH; Hao B; Kline EG; Clancy CJ
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891598
[TBL] [Abstract][Full Text] [Related]
3. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.
van Duin D; Lok JJ; Earley M; Cober E; Richter SS; Perez F; Salata RA; Kalayjian RC; Watkins RR; Doi Y; Kaye KS; Fowler VG; Paterson DL; Bonomo RA; Evans S;
Clin Infect Dis; 2018 Jan; 66(2):163-171. PubMed ID: 29020404
[TBL] [Abstract][Full Text] [Related]
4. The β-Lactams Strike Back: Ceftazidime-Avibactam.
Zasowski EJ; Rybak JM; Rybak MJ
Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015-2017.
Stone GG; Seifert H; Nord CE
Int J Antimicrob Agents; 2020 Sep; 56(3):106045. PubMed ID: 32522673
[TBL] [Abstract][Full Text] [Related]
6. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
[TBL] [Abstract][Full Text] [Related]
7. [In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates].
Hoşbul T; Aydoğan CN; Kaya S; Bedir O; Gümral R; Albay A
Mikrobiyol Bul; 2022 Apr; 56(2):218-229. PubMed ID: 35477226
[TBL] [Abstract][Full Text] [Related]
8.
Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760124
[TBL] [Abstract][Full Text] [Related]
9. In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula.
Sonnevend Á; Ghazawi A; Darwish D; Barathan G; Hashmey R; Ashraf T; Rizvi TA; Pál T
Int J Infect Dis; 2020 Oct; 99():253-259. PubMed ID: 32738488
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).
Ko WC; Stone GG
Ann Clin Microbiol Antimicrob; 2020 Apr; 19(1):14. PubMed ID: 32238155
[TBL] [Abstract][Full Text] [Related]
11.
Chen T; Xu W; Yu K; Zeng W; Xu C; Cao J; Zhou T
Microb Drug Resist; 2021 Mar; 27(3):401-409. PubMed ID: 32721272
[No Abstract] [Full Text] [Related]
12.
Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670424
[TBL] [Abstract][Full Text] [Related]
13. Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of
Mataraci Kara E; Yilmaz M; İstanbullu Tosun A; Özbek Çelik B
Infect Dis (Lond); 2020 Sep; 52(9):616-624. PubMed ID: 32427010
[No Abstract] [Full Text] [Related]
14. Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.
Davido B; Crémieux AC; Vaugier I; Gatin L; Noussair L; Massias L; Laurent F; Saleh-Mghir A
Int J Antimicrob Agents; 2023 Jan; 61(1):106702. PubMed ID: 36476965
[TBL] [Abstract][Full Text] [Related]
15. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.
Zhanel GG; Lawson CD; Adam H; Schweizer F; Zelenitsky S; Lagacé-Wiens PR; Denisuik A; Rubinstein E; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2013 Feb; 73(2):159-77. PubMed ID: 23371303
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment.
Wang F; Zhou Q; Yang X; Bai Y; Cui J
PLoS One; 2021; 16(10):e0258426. PubMed ID: 34648556
[TBL] [Abstract][Full Text] [Related]
17. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
Piérard D; Stone GG
BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the synergy of ceftazidime/avibactam in combination with colistin, doripenem, levofloxacin, tigecycline, and tobramycin against OXA-48 producing Enterobacterales.
Mataraci Kara E; Yilmaz M; Istanbullu Tosun A; Özbek Çelik B
J Chemother; 2020 Jul; 32(4):171-178. PubMed ID: 32375606
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15.
Kazmierczak KM; de Jonge BLM; Stone GG; Sahm DF
J Antimicrob Chemother; 2018 Oct; 73(10):2777-2781. PubMed ID: 30010951
[TBL] [Abstract][Full Text] [Related]
20. Changing Characteristics and
Mavroidi A; Katsiari M; Likousi S; Palla E; Roussou Z; Nikolaou C; Mathas C; Merkouri E; Platsouka ED
Microb Drug Resist; 2020 Jan; 26(1):28-37. PubMed ID: 31386596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
